---
title: "Monash University Study Finds Link Between Low-Dose Aspirin and Reduced Dementia Risk"
url: https://noti.group/monash-university-study-finds-link-between-low-dose-aspirin/
language: en
publisher: "Noti Group"
section: "Health"
published: 2026-10-25T10:21:48.000Z
updated: 2026-10-25T18:04:35.344Z
id: 8f6f5e11-ffc1-403b-99a6-92f9fdec33ce
source: "ScienceDaily Health https://www.sciencedaily.com/releases/2026/10/261024222026.htm"
attribution: "Link to https://noti.group/monash-university-study-finds-link-between-low-dose-aspirin/ and name Noti Group when you quote or summarize this story."
---

# Monash University Study Finds Link Between Low-Dose Aspirin and Reduced Dementia Risk

A groundbreaking study from Monash University has uncovered a significant link between low-dose aspirin and a reduced risk of dementia in older adults with specific genetic characteristics. Researchers analyzed data from over 13,500 participants in the ASPREE Trial, which investigated the effects of aspirin on health outcomes in elderly individuals.

The study's findings suggest that genetic testing could potentially identify those who may benefit from preventive treatments. Scientists discovered significant variations in how aspirin affects dementia risk between individuals with different genetic profiles. This raises questions about whether personalized medicine approaches could be used to target specific populations for aspirin-based prevention strategies.

Researchers focused on genes associated with platelet count, which are small components of the blood that aid in clot formation. By examining genetic variations related to platelet levels, scientists aimed to understand how these differences might impact the effectiveness of aspirin in reducing dementia risk.

The study's results show a striking correlation between low-dose aspirin and a 70 percent lower relative risk of developing dementia among individuals with specific genetic characteristics. The next step will be to investigate the underlying mechanisms behind this association, potentially leading to new avenues for prevention and treatment.

Research has shed light on a potential link between low-dose aspirin and a significantly reduced risk of dementia in individuals with a specific genetic profile.

Among those in the top 20% of platelet count genetic scores, only about 1% of aspirin users developed dementia, whereas approximately 3.3% of participants taking a placebo fell victim to the condition. This translates to roughly a 70% lower relative risk of dementia among those receiving aspirin.

However, this apparent benefit came with a notable safety concern: in the same genetic group, 4.4% of aspirin users experienced major bleeding, compared to 2.1% of placebo recipients.

The findings suggest that an individual's genetic makeup could play a crucial role in determining which dementia prevention strategies are most effective for them.

Dementia is becoming increasingly common, with estimates suggesting that approximately 446,500 people in Australia will be living with the condition by 2026, a number expected to exceed one million by 2065.

The link between dementia and platelet biology has been explored in previous research, which found connections between the condition and platelet activation and aggregation. However, scientists have had limited understanding of how an individual's overall platelet count relates to dementia risk.

Research has now shed new light on this area, identifying a genetic association that points towards platelet biology as a potentially important area of investigation in dementia prevention. This finding is significant because it does not involve the established genetic risk factors typically linked to Alzheimer's disease and other forms of dementia.

Researchers emphasize that more research is needed before medical recommendations can be made based on these findings, particularly regarding the potential benefits of aspirin for different individuals depending on their genetic makeup.

To confirm the findings of this study, researchers plan to investigate whether the link between low-dose aspirin and reduced dementia risk is observed in other populations.

Further research would involve conducting clinical trials specifically among individuals who share a similar genetic profile to those identified in the analysis. This targeted approach aims to provide more conclusive evidence on the potential benefits of aspirin for this specific group.

It's essential that people do not start taking aspirin as a preventative measure against dementia without consulting their doctor, especially considering the increased risk of serious bleeding associated with long-term aspirin use.

If further studies and trials uphold these findings, low-dose aspirin could potentially become an accessible and affordable tool for personalized dementia prevention.

---
Source: [ScienceDaily Health](https://www.sciencedaily.com/releases/2026/10/261024222026.htm)  
Published by Noti Group: https://noti.group/monash-university-study-finds-link-between-low-dose-aspirin/